FPIN's Clinical Inquiries

Screening Mammography for Reducing Breast Cancer Mortality


Am Fam Physician. 2012 Jan 15;85(2):176-183.

Clinical Question

Does screening mammography reduce breast cancer mortality in women 40 to 49 years of age?

Evidence-Based Answer

Screening mammography reduces breast cancer mortality in women 40 to 49 years of age who have an average risk of breast cancer. (Strength of Recommendation: A, based on eight randomized controlled trials [RCTs].) The relative risk reduction in this age group is 15 percent, similar to that of women 50 years and older (14 percent). To prevent one breast cancer death, 1,904 women 40 to 49 years of age must be screened annually for 10 years, compared with 1,339 women 50 to 59 years of age. Although both age groups appear to have a similar relative risk reduction from routine screening, women 40 to 49 years of age have a smaller absolute risk reduction and may experience greater harms from screening compared with older women. These potential harms include false-positive results, diagnosis and treatment for cancer that would not have become clinically evident during the woman's lifetime, false-negative results (i.e., false reassurance), radiation exposure, biopsies, and anxiety.

Evidence Summary

A meta-analysis of seven RCTs (n = 187,091) found that screening mammography every one to two years in women 40 to 49 years of age results in a 15 percent relative risk reduction in breast cancer mortality after 14 years of follow-up (relative risk [RR] = 0.85; 95% credible interval [CrI], 0.73 to 0.99). A Bayesian statistical analysis was used with CrI in place of confidence interval (CI).1 In this meta-analysis, the relative risk reduction is smaller than the 22 percent relative risk reduction in women 50 years and older (RR = 0.78; CrI 0.70 to 0.87).1

In a Cochrane review of seven RCTs (n = 600,000), three trials with adequate randomization showed a 10 percent relative risk reduction in breast cancer mortality (RR = 0.90; 95% CI, 0.79 to 1.02), although this was not statistically significant.2 The other four trials had inadequate randomization. The overall conclusion was an estimated relative risk reduction of 15 percent corresponding to an absolute risk reduction of 0.05 percent (number needed to treat = 2,000).2 The Cochrane authors note that the benefit of screening may have been favorably accentuated because of the inherent bias in reporting the cause of death in these trials.2

A meta-analysis of eight RCTs (n = 348,219) incorporated data from a European trial with a specific focus on patients 40 to 49 years of age.3 This meta-analysis estimated a 15 percent relative risk reduction in breast cancer death (RR = 0.85; CrI, 0.75 to 0.96) and an absolute risk reduction of 0.025 percent (number needed to treat = 4,000).3 Women 50 to 59 years of age in this meta-analysis had a 14 percent relative risk reduction (RR = 0.86; 95% CrI, 0.75 to 0.99).3 Although the estimates of relative risk reduction for these two age groups are nearly identical, the absolute risk reduction is less for women 40 to 49 years of age because of a decreased incidence of baseline disease compared with older women.3

The European RCT (n = 160,921) is the only study that specifically addresses the effectiveness of screening women in their 40s and reflects current screening practices.4 Previous trials of screening mammography for women in their 40s had included women up to 49 years of age at the time of trial entry, and it was unclear how beneficial screening was after they reached 50 years of age. This study was specifically designed to overcome these limitations by enrolling women 39 to 41 years of age and offering screening up to only 48 years of age.4 The reduction in breast cancer mortality noted in the women undergoing screening beginning at 40 years of age was similar to that of previous trials, but the reduction was not statistically significant (RR = 0.83; 95% CI, 0.66 to 1.04).4

Statistical models evaluating mammography screening starting at 40 years of age estimate a small gain (an additional 3 percent reduction in breast cancer deaths) that requires a larger number of additional screenings.5 Furthermore, approximately 60 percent more false-positive results occur per 1,000 women screened at 40 to 49 years of age, leading to a marked increase in potentially unnecessary testing and procedures.5

Recommendations from Others

The U.S. Preventive Services Task Force recommends biennial screening mammography for women 50 to 74 years of age.6 The decision to start regular biennial screening before 50 years of age should be individualized and take into account patient context, including the patient's values regarding specific benefits and harms.6 The American Academy of Family Physicians endorses these recommendations.7 The American Cancer Society recommends yearly mammography starting at 40 years of age.8 The American College of Obstetricians and Gynecologists recommends mammography every one to two years in women 40 to 49 years of age.9 The American College of Physicians recommends that screening mammography decisions be based on patient preference and individualized risk assessment in women 40 to 49 years of age.10

Address correspondence to Poornima Bangalore Krishnaiah, MD, at poorni116@hotmail.com. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

Copyright Family Physicians Inquiries Network. Used with permission.


show all references

1. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(5 pt 1):347–360....

2. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;(1):CD001877.

3. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force Ann Intern Med. 2009;151(10):727–737.

4. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow up: a randomised controlled trial. Lancet. 2006;368(9552):2053–2060.

5. Mandelblatt JS, Cronin KA, Bailey S, et al.; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms [published correction appears in Ann Intern Med. 2010;152(2):136]. Ann Intern Med. 2009;151(10):738–747.

6. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement [published corrections appear in Ann Intern Med. 2010;152(3):199–200, and Ann Intern Med. 2010;152(10):688]. Ann Intern Med. 2009;151(10):716–726W-236.

7. American Academy of Family Physicians. Breast cancer. https://www.aafp.org/online/en/home/clinical/exam/breastcancer.html. Accessed November 29, 2011.

8. Saslow D, Boetes C, Burke W, et al.; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [published correction appears in CA Cancer J Clin. 2007;57(3):185]. CA Cancer J Clin. 2007;57(2):75–89.

9. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 42, April 2003. Breast cancer screening. Obstet Gynecol. 2003;101(4):821–831.

10. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;146(7):511–515.

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net/?o=1025).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or e-mail: questions@fpin.org.

A collection of FPIN's Clinical Inquiries published in AFP is available at https://www.aafp.org/afp/fpin.



Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article